This article is more than 5 years old. Information may no longer be current.

VIDEO: Ado-trastuzumab emtansine plus pertuzumab effective for HER-2–positive breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — Lajos Pusztai, MD, Dphil, medical oncologist at Yale Cancer Center, discusses the impact of the I-SPY 2 trial presented at the American Association for Cancer Research Annual Meeting.

Results showed neoadjuvant treatment with ado-trastuzumab emtansine (Kadcyla, Genentech) plus pertuzumab (Perjeta, Genentech) induced a higher rate of pathologic complete response than the current standard of care, which consists of paclitaxel plus trastuzumab (Herceptin, Genentech).

The therapy also appeared well tolerated.

“The next important question in this study will be about how those who do not achieve pathologic complete response can be salvaged by using adjuvant therapy from the remainder of conductive drugs that they haven’t received in the neoadjuvant setting,” Pusztai told HemOnc Today.